FDA Approved: GAVRETO — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Gavreto (pralsetinib) filed by Genentech, expanding its label for RET fusion–positive cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Thyroid Cancer

Drugs mentioned

• GAVRETO (pralsetinib)

Snippet

SUPPL AP for GAVRETO (PRALSETINIB)